EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: A retrospective database analysis of potential drug interaction

• Main Authors: Kumarakulasinghe, N.B, Syn, N, Soon, Y.Y, Asmat, A, Zheng, H, Loy, E.Y, Pang, B, Soo, R.A
• Other Authors: PATHOLOGY
• Format: Article
• Published: Impact Journals LLC 2020
• Subjects: erlotinib; gefitinib; histamine H2 receptor antagonist; proton pump inhibitor; antineoplastic agent; EGFR protein, human; epidermal growth factor receptor; protein kinase inhibitor; quinazoline derivative; adult; aged; Article; cancer chemotherapy; Charlson Comorbidity Index; cohort analysis; controlled study; drug antagonism; drug use; EGFR gene; female; gene mutation; human; Karnofsky Performance Status; major clinical study; male; medical record review; non small cell lung cancer; overall survival; progression free survival; receptor gene; antagonists and inhibitors; chi square distribution; clinical trial; disease exacerbation; disease free survival; drug interaction; enzymology; factual database; genetics; Kaplan Meier method; lung tumor; metabolism; middle aged; mortality; multicenter study; multivariate analysis; mutation; proportional hazards model; retrospective study; risk assessment; risk factor; Singapore; time factor; treatment outcome; very elderly; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Databases, Factual; Disease Progression; Disease-Free Survival; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Receptor, Epidermal Growth Factor; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/175449
• Institution: National University of Singapore

10.18632/oncotarget.13458